AI-generated summary
The authors report a randomized pilot trial of 26 people with diabetic peripheral neuropathy, comparing local photobiomodulation alone, local photobiomodulation plus intravascular laser irradiation of blood, and a sham control over 12 sessions. Neuropathic pain decreased over time, with a significant reduction in the local photobiomodulation group, but no clear difference between groups was found. The small pilot design and short follow-up limit interpretation.
- Participants
- 26
- Who or what was studied
- Individuals with diabetic peripheral neuropathy
- Limits stated in the abstract
- The abstract states the pilot design, small sample size, baseline pain heterogeneity, potential placebo effects, and short follow-up limit interpretation.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Diabetic peripheral neuropathy is a disabling chronic complication of diabetes mellitus, associated with neuropathic pain, sensory dysfunction, and reduced quality of life. Because pharmacological treatments often provide only partial relief, photobiomodulation therapy (PBMT) has emerged as a promising non-pharmacological strategy with metabolic, anti-inflammatory, and neuromodulatory effects. To assess the feasibility of local PBMT, administered alone or combined with intravascular laser irradiation of blood (ILIB), and to explore preliminary short-term changes in neuropathic pain, neuropathic symptoms, and sensory responses in individuals with diabetic peripheral neuropathy. This prospective randomized controlled pilot trial included 26 participants allocated to three groups: local PBMT, local PBMT combined with ILIB, and sham control. All randomized participants completed 12 sessions over 23 days. Neuropathic pain intensity was assessed using the Visual Analog Scale, and neuropathic symptoms were evaluated using the Michigan Neuropathy Screening Instrument. Friedman and McNemar tests were used for exploratory within-group and paired analyses, and a linear mixed-effects model evaluated pain trajectory over time. Neuropathic pain intensity decreased across the five assessment points (p < 0.001), with significant intragroup reduction in the local PBMT group (p = 0.007). Improvements were observed in selected symptoms, including numbness, cramps, and dry skin with fissures. The mixed-effects model showed a significant effect of time on pain reduction (beta = -0.78; p = 0.001), although no significant group x time interaction was detected. Local PBMT, administered alone or combined with ILIB, was feasible in this outpatient pilot trial and was followed by preliminary short-term reductions in neuropathic pain and selected neuropathic symptoms. However, no definitive between-group superiority was demonstrated, and the findings should be interpreted cautiously because of the pilot design, small sample size, heterogeneity in baseline pain intensity, potential placebo effects, and short follow-up period.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation therapy, Neuropathy, Photobiomodulation, Heterogeneity, Sample size, Laser, Sham. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.